Prostate Cancer Trial, Recruiting NCT03789253 Sponsor: National Taiwan University Hospital Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT03789253
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with prostate cancer (a specific type called adenocarcinoma), confirmed by a tissue or cell sample.
  • You are currently on, or have previously been on, an "active surveillance" plan (a watchful waiting approach instead of immediate treatment) managed at National Taiwan University Hospital (NTUH).
  • You have had, or are planning to have, a prostate biopsy to check whether the cancer has grown or changed since your original diagnosis.

Who may not be able to join:

  • You have already received chemotherapy, radiation therapy to the pelvic area, or hormone therapy (to lower testosterone) before a tissue sample was taken from your prostate through surgery or biopsy.
  • You are not willing to sign the consent form agreeing to take part in the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yeong-Shiau Pu, PhD, National Taiwan University

Phone: 886-2-23123456

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
2 January 2019
Est. completion
31 July 2030

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Gene expression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov